NasdaqGS - Delayed Quote • USD
Genmab A/S (GMAB)
At close: May 9 at 4:00 PM EDT
After hours: May 9 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | 0.32 | 0.31 | 1.08 | 1.49 |
| Low Estimate | 0.31 | 0.3 | 1.08 | 1.44 |
| High Estimate | 0.33 | 0.33 | 1.08 | 1.54 |
| Year Ago EPS | 0.3 | 0.47 | 0.96 | 1.08 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 12 | 11 |
| Avg. Estimate | 719.94M | 754.34M | 2.86B | 3.44B |
| Low Estimate | 677.08M | 718.53M | 2.71B | 3.16B |
| High Estimate | 778.68M | 788.63M | 2.93B | 3.67B |
| Year Ago Sales | 613.62M | 692.39M | 2.39B | 2.86B |
| Sales Growth (year/est) | 17.30% | 8.90% | 19.40% | 20.40% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 2.18 | 3.14 | 3.25 | 0.14 |
| EPS Actual | 0.3 | 0.47 | 0.14 | 0.29 |
| Difference | -1.88 | -2.67 | -3.11 | 0.15 |
| Surprise % | -86.20% | -85.00% | -95.70% | 107.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.32 | 0.31 | 1.08 | 1.49 |
| 7 Days Ago | 0.3 | 0.3 | 1.1 | 1.5 |
| 30 Days Ago | 0.3 | 0.3 | 1.09 | 1.5 |
| 60 Days Ago | 3.85 | 3.97 | 14.62 | 18 |
| 90 Days Ago | 3.84 | 4.19 | 15.12 | 19.34 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | -- | -- |
| Up Last 30 Days | 1 | 1 | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | GMAB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 6.70% | -- | -- | 8.60% |
| Next Qtr. | -34.00% | -- | -- | 11.90% |
| Current Year | 12.50% | -- | -- | 5.60% |
| Next Year | 38.00% | -- | -- | 13.20% |
| Next 5 Years (per annum) | 13.10% | -- | -- | 11.07% |
| Past 5 Years (per annum) | -30.41% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/3/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/30/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/4/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/27/2024 |
| Maintains | Morgan Stanley: Underweight to Underweight | 3/26/2024 |
| Maintains | Truist Securities: Buy to Buy | 3/26/2024 |
Related Tickers
ASND Ascendis Pharma A/S
133.13
-0.60%
BAVA.CO Bavarian Nordic A/S
162.90
+0.25%
IONS Ionis Pharmaceuticals, Inc.
39.47
-1.72%
BPMC Blueprint Medicines Corporation
108.34
-0.40%
BGNE BeiGene, Ltd.
168.64
+2.55%
ALK-B.CO ALK-Abelló A/S
153.30
-0.13%
ARGX argenx SE
382.55
-0.91%
INCY Incyte Corporation
53.50
-0.02%
LEGN Legend Biotech Corporation
45.52
-0.44%
ALNY Alnylam Pharmaceuticals, Inc.
151.37
-0.60%